Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery

J Immunol. 2006 Jul 1;177(1):177-91. doi: 10.4049/jimmunol.177.1.177.

Abstract

We investigated the ability of a plasmid-derived IL-21 delivered alone or in combination with the IL-15 gene to regulate immune responses to the HIV-1 envelope (Env) glycoprotein induced by DNA vaccination. Mice were injected with the gp140DeltaCFI(HXB2/89.6) vector expressing a modified Env glycoprotein with C-terminal mutations intended to mimic a fusion intermediate, in which the most divergent region encoding the variable V1, V2, and V3 domains of CXCR4-tropic HxB2 virus was replaced with the dual-tropic 89.6 viral strain. Using a recombinant vaccinia virus expressing 89.6 Env glycoprotein (vBD3) in a mouse challenge model, we observed that IL-21 plasmid produced sustained resistance to viral transmission when injected 5 days after DNA vaccination. Moreover, IL-21 in a synergistic manner with IL-15 expression vector augmented the vaccine-induced recall responses to the vBD3 challenge compared with those elicited by immunization in the presence of either cytokine alone. The synergistic combination of IL-21 and IL-15 plasmids promoted expansion of CD8+CD127+ memory T cell pools specific for a subdominant HLA-A2-restricted Env(121-129) epitope (KLTPLCVTL). Our results also show that coimmunization with IL-21 and IL-15 plasmid combination resulted in enhanced CD8+ T cell function that was partially independent of CD4+ T cell help in mediating protection against vBD3 challenge. Furthermore, the use of IL-21 and IL-15 genes was able to increase Ab-dependent cellular cytotoxicity and complement-dependent lysis of Env-expressing target cells through augmentation of Env-specific IgG Ab levels. These data indicate that the plasmid-delivered IL-21 and IL-15 can increase the magnitude of the response to DNA vaccines.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / genetics*
  • Animals
  • Antibody-Dependent Cell Cytotoxicity / genetics
  • CD8-Positive T-Lymphocytes / immunology
  • Combined Modality Therapy
  • Female
  • Gene Products, env / administration & dosage
  • Gene Products, env / biosynthesis
  • Gene Products, env / genetics*
  • Gene Transfer Techniques*
  • HIV Antibodies / biosynthesis
  • HIV Antibodies / physiology
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Immunization, Secondary
  • Interleukin-15 / administration & dosage
  • Interleukin-15 / genetics*
  • Interleukin-21
  • Interleukins / administration & dosage
  • Interleukins / genetics*
  • Interleukins / physiology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Transgenic
  • Neutralization Tests
  • Rabbits
  • Vaccines, DNA / administration & dosage
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology*
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology
  • env Gene Products, Human Immunodeficiency Virus

Substances

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Gene Products, env
  • HIV Antibodies
  • Interleukin-15
  • Interleukins
  • Vaccines, DNA
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1
  • Interleukin-21